0000899243-19-013097.txt : 20190510 0000899243-19-013097.hdr.sgml : 20190510 20190510172515 ACCESSION NUMBER: 0000899243-19-013097 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190508 FILED AS OF DATE: 20190510 DATE AS OF CHANGE: 20190510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Welch David F CENTRAL INDEX KEY: 0001399122 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-49908 FILM NUMBER: 19816118 MAIL ADDRESS: STREET 1: C/O INFINERA CORPORATION STREET 2: 140 CASPIAN COURT CITY: SUNNYVALE STATE: CA ZIP: 94089 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytoDyn Inc. CENTRAL INDEX KEY: 0001175680 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 753056237 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 BUSINESS PHONE: 360-980-8524 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER COMPANY: FORMER CONFORMED NAME: CYTODYN INC DATE OF NAME CHANGE: 20031114 FORMER COMPANY: FORMER CONFORMED NAME: REXRAY CORP DATE OF NAME CHANGE: 20020617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-08 0 0001175680 CytoDyn Inc. CYDY 0001399122 Welch David F 1111 MAIN STREET, SUITE 660 VANCOUVER WA 98660 1 0 0 0 Common Stock 2019-05-08 4 M 0 166666 0.40 A 1129999 I See footnote Common Stock 2019-05-08 4 M 0 600000 0.40 A 1729999 I See footnote Common Stock 2019-05-08 4 M 0 500000 0.40 A 2175280 I See footnote Common Stock 2019-05-08 4 M 0 384615 0.40 A 2559895 I See footnote Common Stock 2019-05-08 4 A 0 383333 A 2112332 I See footnote Common Stock 2019-05-08 4 A 0 442307 A 3002202 I See footnote Warrant (Right to Buy) 0.75 2019-05-08 4 D 0 166666 D 2019-01-10 2021-01-28 Common Stock 166666 0 I See footnote Warrant (Right to Buy) 0.40 2019-05-08 4 A 0 166666 A 2019-01-10 2021-01-28 Common Stock 166666 166666 I See footnote Warrant (Right to Buy) 0.40 2019-05-08 4 M 0 166666 0.00 D 2019-01-10 2021-01-28 Common Stock 166666 0 I See footnote Warrant (Right to Buy) 0.75 2019-05-08 4 D 0 600000 D 2019-01-10 2023-02-16 Common Stock 600000 0 I See footnote Warrant (Right to Buy) 0.40 2019-05-08 4 A 0 600000 A 2019-01-10 2023-02-16 Common Stock 600000 600000 I See footnote Warrant (Right to Buy) 0.40 2019-05-08 4 M 0 600000 0.00 D 2019-01-10 2023-02-16 Common Stock 600000 0 I See footnote Warrant (Right to Buy) 0.75 2019-05-08 4 D 0 500000 D 2019-01-10 2023-09-14 Common Stock 500000 0 I See footnote Warrant (Right to Buy) 0.40 2019-05-08 4 A 0 500000 A 2019-01-10 2023-09-14 Common Stock 500000 500000 I See footnote Warrant (Right to Buy) 0.40 2019-05-08 4 M 0 500000 0.00 D 2019-01-10 2023-09-14 Common Stock 500000 0 I See footnote Warrants (Right to Buy) 0.75 2019-05-08 4 D 0 384615 D 2019-01-10 2022-09-08 Common Stock 384615 0 I See footnote Warrants (Right to Buy) 0.40 2019-05-08 4 A 0 384615 A 2019-01-10 2022-09-08 Common Stock 384615 384615 I See footnote Warrants (Right to Buy) 0.40 2019-05-08 4 M 0 384615 0.00 D 2019-01-10 2022-09-08 Common Stock 384615 0 I See footnote The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. The reported securities of the Company are held by David Welch Tr Ua 03/02/2000 Welch Charitable Remainder Unitrust Agreement II (the "Trust"), for which Dr. Welch is a trustee. On May 8, 2019, the Company entered into Warrant Exercise Agreements with LRFA and the Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Dr. Welch, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants. /s/ Michael D. Mulholland, as attorney-in-fact 2019-05-10